Navigation Links
Pluromed, Inc. Signs Agreement with Boston Scientific
Date:10/8/2009

Boston Scientific to distribute Pluromed's BackStop™ device, a rapid phase transition gel used in the treatment of Kidney Stones.

Woburn, Massachusetts (PRWEB) October 9, 2009 -- Pluromed, Inc. has announced that it has entered into an alliance with Boston Scientific Corporation (NYSE: BSX) regarding Pluromed's BackStop™ product, a device used in ureteroscopic kidney stone management procedures. Boston Scientific has acquired the worldwide distribution rights to BackStop. The financial terms of the agreement were not disclosed.

Kidney stone disease is estimated to affect millions of people worldwide. A common method of treating these stones is intracorporeal lithotripsy where the stones are fragmented using a laser or other energy modality in a minimally invasive procedure. Backstop™ is based on Pluromed's proprietary Rapid Transition Polymers™ (RTP™) that are liquid at low temperature and transition to a gel at body temperature; the transition is reversible via cooling and the gel is completely dissolvable. The BackStop gel forms a plug above the stones in the ureter and is designed to prevent stone migration during the procedure. After stone fragmentation is complete, the gel is dissolved with saline and exits the body. The BackStop product offers the potential to reduce operating time and complexity, and improve "stone free" rates for patients.

"We are very pleased to work with with Boston Scientific," said John Merhige, Pluromed's Vice President of Market Development. "BSC is the market leader with the resources and expertise to get the BackStop product into the hands of urologists." The BackStop device is approved for sale in Europe, Canada and the United States.

Jean-Marie Vogel, Pluromed's CEO, said, "This alliance represents an important event in the evolution of Pluromed. The proceeds from the agreement allow us to further invest in growing our core cardiovascular business, and with Boston Scientific distributing the BackStop product, we anticipate a successful launch and ongoing growth."

Pluromed and Boston Scientific will be working closely on integrating the BackStop product into BSC's systems in anticipation of the worldwide product launch.


About Pluromed, Inc.
Pluromed, Inc., Woburn, Massachusetts, founded in 2003, is pioneering the use of atraumatic gel plugs to improve the safety, efficacy and economics of medical interventions. These products address a broad surgery market that includes cardiac and vascular surgery, prostate, kidney and liver surgery, plastic/reconstructive surgery, trauma/battlefield applications and the treatment of kidney stones. They are based on the Company's patented rapid phase transition polymer technology; Pluromed Rapid Transition Polymers™ (RTP™) are liquid at low temperature and quickly transition to a high viscosity gel at body temperature. For more information, please visit www.pluromed.com

About Boston Scientific Corporation
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3011074.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. SEO Consultant Top Rank Web Designs Gives Away 250 Free Websites
2. /R E P E A T -- DiagnoCure signs distribution agreement in the UK for its colorectal cancer test/
3. DiagnoCure signs distribution agreement in the UK for its colorectal cancer test
4. AdaptaVan, LLC Signs Two New Dealers: Company's Wheelchair Accessible Vans Now Available in North Carolina and Missouri
5. The MED Group Signs Preferred Supplier Agreement for Masimo SET(R) Pulse Oximetry Solutions
6. Rapid Fire Marketing Signs 5 Year Agreement
7. Osseon Signs International Distribution Agreement With MBA Incorporado
8. New device finds early signs of eye disease in preemies
9. GENova Biotherapeutics signs LOI with Korean university for stem cell research and patents sharing
10. GENova Biotherapeutics signs engagement agreement with PacificWave Partners Limited
11. Haemonetics Signs Comprehensive Agreement with Blood Centers of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology: